Sabitlenmiş Tweet
Medable
5.1K posts

Medable
@medableinc
Empowering patients with global access to new therapies through direct-to-patient clinical trial technology.
Palo Alto Katılım Şubat 2013
1K Takip Edilen3.6K Takipçiler

Did you know that manual document reconciliation between trial systems consumes at least one-third of clinical data managers' and clinical research associates’ time?
This means your highly trained professionals are spending their days chasing files between platforms rather than moving science forward.
Medable’s TMF Agent takes on the high-volume work of organizing and filing trial documents across studies. Your team reviews, approves, stays in control where it matters, and gets their time back.
That shift is a game changer and frees up real strategic capacity.
DM this account to learn more! 📥
________
#clinicalresearch #TMF #clinicaltrials #agenticAI
English

AI is unlocking a new wave of therapies faster than ever before. But unless we fix the operational bottlenecks in clinical trials, those breakthroughs will sit waiting.
The future of medicine doesn’t just depend on discovery. It depends on execution.
Andrew Mackinnon outlines where the system is breaking and what it will take to fix it.
Read his full article here: themedicinemaker.com/issues/2026/ar…
________
#clinicaltrials #clinicalresearch #healthcare #agenticAI
English

Team Medable on-site at NVIDIA GTC! 📸
There’s still plenty of excitement around AI, but more importantly, there’s a growing focus on how agentic AI is actually being applied to move science forward—not someday, but now.
It was a busy day of productive meetings. Exciting times ahead! 🔥
________
#clinicaltrials #clinicalresearch #agenticAI #science

English

The journey from discovery to treatment is one of the hardest challenges in healthcare. 🔬
Today at the Miami CEO event, Medable CEO Dr. Michelle Longmire is joining the panel “Translating Science into Medicine” to explore how leaders across the ecosystem can accelerate that journey and deliver therapies to patients sooner.
Speakers:
- Anish Bhatnagar, CEO, Soleno Therapeutics
- Bill Hait, Chief Scientific Advisor, AACR; former Global Head, Janssen R&D
- Michelle Longmire, CEO, Medable
- Sondra Neale Smyrnios, SVP, Clinical & Technical Operations, Newleos
- Moderator: Jeremy Levin, Chair, Ovid Therapeutics
Hosted by Longwood Healthcare Leaders.
Learn more here: longwoodhealthcareleaders.com/miamiceo
________
#clinicaltrials #science #healthcare #clinicaldevelopment

English

Every delay in clinical development is time that patients don’t have.
In the latest @pharmaphorum podcast episode, Andrew Mackinnon discusses how generative and agentic AI can close the “white space” in R&D while keeping human oversight, participant safety, and regulatory trust at the center.
The end result? Therapies reach patients faster.
👉 Listen here: pharmaphorum.com/rd/ai-clinical…
________
#clinicaltrials #clinicalresearch #healthcare #agenticAI
English

Most “AI in clinical trials” is just analysis after the fact. What if it could actually move the work forward?
Agents that understand messy data. Agents that unify it across systems. Agents that take action.
That’s what Medable’s Agent Studio is built for. Fiachra Matthews breaks it down below.
________
#clinicaltrials #clinicalresearch #agenticAI #healthcare
English

"I hope in the future we abolish phrases like 'male-dominated.'"
As we enter International Women's Month and reflect on this year’s theme, 'leading the change,' the women of Medable shared what they hope the future holds for the next generation—professionally, personally, and beyond.
Take a listen below! ⬇️⬇️
________
#IWD #InternationalWomensMonth #lifesciences #healthcare
English

Cell & gene therapies have delivered life-changing outcomes, but their long-term success depends on follow-up models that are not meeting the needs of participants and are no longer fit for purpose.
Traditional long-term follow-up (LTFU) studies place heavy logistical burdens on patients and sites, leading to low participation rates and knowledge gaps. At least 20% of CAR T-cell therapy patients drop out of studies entirely, and 80% drop by year 5.
It’s time to rethink the model.
This session with Medable's CMO, Dr. Pamela Tenaerts, explores a digital-first approach to LTFU designed to sustain participant engagement, reduce attrition, and maintain scientific and regulatory rigor over time.
Join us tomorrow at Endpoints News' C> Summit to learn how remote and hybrid interaction, seamless transitions from parent trials, and patient-centered data capture can strengthen safety monitoring, improve data quality, and better reflect the real-world impact of advanced therapies.
Register here: events.endpoints.news/cgday26
________
#clinicaltrials #clinicalresearch #cellandgenetherapies #healthcare
English

"Decentralized trial tools are settling into routine use as sponsors and sites apply them selectively to address protocol-specific operational needs," agree Medable's Dr. Pamela Tenaerts and Tufts CSDD's Ken Getz.
This will be a main topic of conversation at tomorrow's Innovation Evidence Workshop, hosted by Tufts CSDD & Medable.
This event will bring together pharmaceutical R&D executives and regulatory representatives to examine the use and impact of virtual and remote clinical trial technologies, experiences with agentic-AI-enabled processes supporting clinical research, and the challenges and opportunities of deploying transformative innovations while adhering to ICH E6 R3 guidelines.
Get a glimpse of the insights shared tomorrow from Tenaerts and Getz here: insights.citeline.com/pink-sheet/r-a…
________
#clinicaltrials #clinicalresearch #decentralizedtrials #digitalhealth #healthcare
English

Experience is everything in oncology trials for patients, sites, and investigators, especially in an environment that demands precision, speed, and full transparency. In this live demonstration, Rana Khan will showcase an end-to-end eCOA workflow from both the patient and site perspective during an active study, highlighting how symptom reporting and episodic events are captured and managed in real time.
The session concludes with a preview of Medable's PI Summary Agent, an AI assistant embedded within the eCOA workflow, supporting the PI in ongoing review and signature without replacing PI oversight or blocking site or participant activities.
👉 Secure your spot at tomorrow's event here: event.on24.com/wcc/r/5193469/…
________
#clinicaltrials #clinicalresearch #eCOA #healthcare

English

Let’s ask a trick question. Do you think your organization’s data is ready for AI or AI agents?
In a landscape defined by speed, complexity, and constant change, progress doesn’t come from waiting for ideal conditions. It comes from taking the first step. And with agentic AI, you can start now.
Learn more here: medable.com/knowledge-cent…
________
#clinicaltrials #clinicalresearch #healthcare #agenticAI
English

Assessment and instrument translations can bring global study deployment to a grinding halt. 🫠
Back-and-forth files. Version confusion. Validation headaches.
It doesn't have to be this way.
Rana Khan demos below how we built localization into eCOA the right way.
________
#clinicaltrials #clinicalresearch #healthcare #eCOA #clinicaldevelopment
English
Medable retweetledi

📣 Today, Medable launches an AI agent for research sites to reduce burden and assist principal investigators in the oversight and monitoring of eCOA data. Released just after Medable’s TMF and CRA agents, the PI Summary Agent continues the rapid rollout of function-specific agentic capabilities designed to maximize investigator capacity and accelerate site workflows.
👉 Learn more here: medable.com/newsroom/medab…

English
Medable retweetledi

Everyone wants faster trials, but few are really fixing what slows them down.
In this Q&A, Andrew Mackinnon reveals how Agent Studio, featuring CRA and TMF agents, is engineered to cut study timelines, reduce administrative burden, and unlock parallel execution across larger networks, all without compromising data integrity or compliance.
Read here: clinicaltrialvanguard.com/executiveinter…
________
#clinicaltrials #clinicalresearch #agenticAI #healthcare
English

If your eCOA RFI is just a feature checklist, you’re setting yourself up for problems later.
“Do you support X?” is easy to answer. “Prove your uptime, implementation track record, and audit history” is harder.
The difference shows up mid-study, when switching vendors isn’t an option.
Here’s how to write an RFI that protects you before you sign: medable.com/knowledge-cent…
_________
#clinicaltrials #clinicalresearch #eCOA #healthcare
English


